Literature DB >> 11157895

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.

R Dagan1, K P Klugman, W A Craig, F Baquero.   

Abstract

Clinical outcome is dependent upon antibiotic-mediated bacterial eradication in a number of infections. However, in respiratory tract infections, the need for bacterial eradication has been controversial. Clinical data are now available that support the need for active bacterial eradication in otitis media. This may also be the case for other respiratory tract infections. An increase in antimicrobial resistance reduces the probability of achieving eradication. Conversely, failure to eradicate bacteria may promote the emergence and dissemination of antimicrobial-resistant clones. Pharmacokinetic/pharmacodynamic parameters can be used to predict the bacteriological efficacy of antimicrobial therapy. In conclusion, the aim of antimicrobial therapy in respiratory tract infections should be the eradication of the infecting organism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157895     DOI: 10.1093/jac/47.2.129

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  37 in total

1.  Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models.

Authors:  Jenny Dahl Knudsen; Inga Odenholt; Helga Erlendsdottir; Magnus Gottfredsson; Otto Cars; Niels Frimodt-Møller; Frank Espersen; Karl G Kristinsson; Sigurdur Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

2.  The Advantage of Bactericidal Drugs in the Treatment of Infection.

Authors:  Jeffrey Alder; Barry Eisenstein
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

3.  Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo.

Authors:  Laura R Marks; G Iyer Parameswaran; Anders P Hakansson
Journal:  Infect Immun       Date:  2012-05-29       Impact factor: 3.441

4.  Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid.

Authors:  Pyry A J Välitalo; Koen Griffioen; Matthew L Rizk; Sandra A G Visser; Meindert Danhof; Gaori Rao; Piet H van der Graaf; J G Coen van Hasselt
Journal:  Pharm Res       Date:  2015-12-01       Impact factor: 4.200

Review 5.  Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.

Authors:  C Andrew DeRyke; Su Young Lee; Joseph L Kuti; David P Nicolau
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Impact of amoxicillin, associated or not with clavulanic acid, on pharyngeal colonization and selection of Streptococcus pneumoniae resistance in children under 5 years of age.

Authors:  Alvaro Díaz Conradi; Esther Calbo; Eva Cuchí; Roger Garcia Puig; César García-Rey; Luis Tobeña Boada; Marisol Díaz-Infantes; José Emilio Martín-Herrero; Javier Garau
Journal:  Eur J Pediatr       Date:  2006-10-11       Impact factor: 3.183

8.  Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

9.  Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.

Authors:  Michael E Pichichero; Gary V Doern; Joseph L Kuti; David P Nicolau
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.

Authors:  T M File; H Lode; H Kurz; R Kozak; H Xie; E Berkowitz
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.